Radial Emphasizes Accelerated TMS Opportunity in Treatment-Resistant Depression

According to a recent LinkedIn post from Radial, the company is drawing attention to accelerated transcranial magnetic stimulation (TMS) as a non‑medication option for treatment‑resistant depression, which it notes affects roughly one in three people diagnosed with depression. The post describes accelerated TMS as an FDA‑cleared therapy that uses magnetic pulses to target brain circuits involved in depression and is reportedly covered by most major insurers.

The company’s LinkedIn post highlights an apparent strategic focus on addressing awareness gaps, suggesting that many eligible patients are unfamiliar with accelerated TMS despite coverage by major payers. For investors, this emphasis on an existing, reimbursed technology with a large underpenetrated patient population could imply a growth-oriented market opportunity in brain medicine services, contingent on Radial’s ability to scale patient acquisition and navigate clinical and regulatory expectations.

As shared in the post, Radial positions itself around solving the problem of low awareness rather than drug development, which may indicate a comparatively asset‑light, service‑driven model centered on care delivery and patient access. If this positioning is accurate, the company’s financial trajectory could be influenced more by marketing effectiveness, provider partnerships, and reimbursement dynamics than by traditional R&D risk, situating Radial within the broader trend toward novel, non‑pharmacologic mental health interventions.